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Several KPIs were examined, but the study focuses on the mean pharmaceutical 
cost per patient, which was then adjusted to the case mix of the units, by using a 
hospital clinical weight indicator, estimated as the weighted average of particular 
incidents, based on GR-DRG data. The results were statistically analysed, in order 
to group the changes, before and after the indicator’s adjustment, per hospital size 
category and assess hospitals’ relative ranking. Results: The results reveal that 
there was a significant -but diminishing as the bed number increases- rise in the 
mean pharmaceutical cost per patient for three categories (25.49%, 14.23%, 11.74% 
increase for hospitals with less than 100, 101-250 and 251-400 beds, respectively) 
after the indicator was adjusted to the hospitals’ clinical workload. For hospitals 
with more than 400 beds, the mean pharmaceutical cost per patient decreased 
by 15.38%, after the adjustment. The results also indicate significant changes in 
hospital ranking, even within the 4 categories, ranging from a 34 places ranking 
rise for Onassis Cardiac Surgery Centre, to a 21 places ranking drop for the G.H. of 
Thessaloniki ‘Agios Dimitrios’. ConClusions: Hospitals with more severe than 
average incidents, (cancer hospitals, cardiac surgery centres, etc) improved their 
performance and relative ranking, while small health centres and regional hospi-
tals reported worse results after the indicators’ adjustment. The study concludes 
that clinical workload should be incorporated in hospitals’ pharmaceutical cost 
assessment.
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objeCtives: The objective of this work is to set a cost benefit analysis of the use 
of fibrin sealant patch as supportive treatment in surgery for improvement of 
hemostasis, to promote tissue sealing and for suture support in surgery in those 
cases where standard techniques are not adequate. Methods: Efficacy data were 
obtained from a systematic literature review. The analysis of the costs of hospitali-
zation was conducted on the basis of detection of actual costs, observed from the 
point of view of the hospital. We performed a cost benefit analysis of the use of fibrin 
sealant patch valuing the hospitalization and the consequent use of resources. The 
results of the economic evaluation were subjected to sensitivity analysis, building a 
stochastic simulation with 1000 repetitions within a normal distribution. Results: 
In the group of patients treated with fibrin sealant patch it was observed the 
decrease of the duration of hospitalization vs. the group of patients treated with 
standard techniques: on average 2.66 days, within a range between 0.55 and 11.80 
days. The cost per day of hospitalization was estimated at Euro 206.00: this led to 
a saving in terms of lower costs for the hospital, quantifiable in 549 Euro, from a 
minimum of 103 Euro and a maximum of 2431 Euro. The use of fibrin sealant patch 
led then an average savings of about 304.00 Euro per patient with a cost-benefit ratio 
equal to 2.24 (min. 00.42 - max. 9.93). Overall the results of the sensitivity statistics 
confirm a lower length of stay associated with fibrin sealant patch than standard 
care. ConClusions: The analysis shows the positive role of fibrin sealant patch 
as supportive treatment in surgery where standard techniques are revealed not 
adequate, with decreased postoperative complications, shorter hospital stays and 
reducing hospital costs.
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objeCtives: Personalized medicine (PM) consists of a customized approach consid-
ering individual biological and genetic characteristics to prevent, diagnose or treat 
a medical condition. Although health benefits of PM have been demonstrated, its 
economic impact is not established. The aim of this review was to explore its cost-
effectiveness and summarize the key parameters in every therapeutically health 
areas. Methods: A systematic review of economic evaluations was performed 
using the PICO method. Population consisted of patients who might benefit from 
PM; intervention and comparators were PM and usual care and outcomes were 
results of economic evaluations. The literature search was performed with the NHS 
EED filters using Medline, Embase and Pubmed from 2004 to 2014. Eligible articles 
were economic evaluations, with preventive, diagnostic or therapeutic interven-
tions in PM. Results: A total of 76,488 studies were identified and 213 met the 
inclusion criteria. Cost-utility studies were the most frequent (60.1%), followed 
by cost-effectiveness studies (32.1%) with a healthcare-payer perspective (67.9%). 
Time horizon varied between 28 days and lifetime. Cancer was the most evaluated 
therapeutic field (46.9%) followed by cardiovascular diseases (19.2%) and neurologic 
and psychological diseases (10.3%). A total of 39.9% of the studies were conducted 
in the United States. Adjusted 2015USD ICERs varied from dominant to $9,780759 
per quality adjusted life year (QALY). Among these, 44% have an ICER of $50,000/
QALY or less, while 57% have an ICER of $100,000/QALY or less. Overall, a total of 
147 studies compared their ICER to the reference threshold established by their 
country. Among the ICERs presented, 60.2% were reported as cost-effective (15.3% 
were dominant) and 39.8% non cost-effective. ConClusions: Despite a high het-
erogeneity among the studies, most of them suggest that personalized medicine 
could be cost-effective.
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for the delay in indexing of publications, we included all studies with a publica-
tion date of 2014 that were indexed in PubMed up to 1 June 2015. Results: The 
search identified 1,870 articles published in 2014. Of these, 975 met the inclusion 
criteria and were subcategorised according to topic. The greatest number, 13%, 
were conducted in patients with cardiovascular diseases, with 11% in musculo-
skeletal disorders, 10% each in cancer and digestive disorders, 8% in mental health 
disorders, 7% each in infective disease or acute care, and 6% each in respiratory, 
endocrine and urogenital disorders, and in general populations or healthcare set-
tings. All other disease areas were relatively underrepresented, accounting for 2% 
or fewer of the relevant publications. ConClusions: Despite product pipelines 
being weighted towards new cancer drugs and the challenges in demonstrating 
their cost-effectiveness, cancers are relatively under-represented in recent stud-
ies assessing economic burden. The reasons why costs may be less important an 
outcome in cancer than in cardiovascular or musculoskeletal diseases are unclear, 
but may reflect a more established, often generic or surgical, therapeutic portfolio.
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objeCtives: Ultra orphan therapies are indicated for rare diseases affecting less 
than a few thousand patients. The annual and lifetime per patient cost of these 
treatments have generated controversy and policy questions regarding cost effec-
tiveness and reimbursement. The objective of this analysis was to review all avail-
able cost effectiveness studies and develop lessons for policy development for ultra 
orphan therapies. Methods: Fifteen European Medicines Agency (EMA) and Food 
and Drug Administration (FDA) approved ultra orphan drugs were identified and 
reviewed for their published cost effectiveness through studies in peer-reviewed 
journals and Health Technology Assessments (HTAs). Data was collected for: (1) 
Product (2) Indication (3) Model design and assumptions (4) Author of the analy-
sis (manufacturer, HTA or academic group) (5) Cost effectiveness results and (5) 
Sensitivity analysis results. All cost effectiveness ratios were converted to 2013 US 
dollar amounts using historical currency conversion rates. Results: For fifteen 
EMA and FDA approved ultra orphan therapies, eight cost effectiveness studies 
were identified for seven products (50%). Four of these studies were conducted by 
the sponsor (as part of the HTA submission), two were conducted by HTAs and two 
were from academic groups. All models were developed for a life time horizon. 
In the base case scenario, the median base case incremental cost effectiveness 
ratio (ICER) was $591,200 per quality adjusted life years (QALYs) (range: $391,120 
to $7,425,000). The sensitivity analyses results had a median ICER of $1,958,674 
per QALY, with a maximum ICER of $10,395,000. All reported ICERs exceeded the 
maximum accepted thresholds for end of life care therapies. ConClusions: 
Review of cost effectiveness studies for ultra orphan therapies shows that none 
were able to show ICERs within typical thresholds. These results suggest a need 
for new policy regarding acceptable threshold, or type of models for assessing the 
cost effectiveness of ultra orphan therapies.
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objeCtives: As in most European countries, spending on pharmaceuticals has 
also been cut in recent years in Italy through a series of measures, including price 
reduction and boosting of off-patent drugs prescription. Laws 338/2000 and 405/2001 
incentivised the use of generic drugs and introduced patients’ co-payment if they 
preferred a branded vs off-patent drug. The aim of this study was to analyse the 
consumption and expenditure trend for off-patent drugs in Italy since the intro-
duction of these new measures. Methods: Off-patent (branded and unbranded) 
drug consumption and expenditure indicators from 2004 (first year in which net 
expenditure was available) to 2013 (last available year) were analysed from the 
Observatory on the Use of Medicines (OSMED) published reports. Results: In 2004 
consumption by defined daily dose (DDD) per 1,000 habitants was 166.8 (21.7% on 
total DDD), while in 2013, it was 663.0 (64.3% on total DDD) for territorial drugs. 
Per-capita expenditure was € 22 (10.1% of net territorial expenditures) in 2004 and 
€ 62.4 in 2013 (41.5% of net territorial expenditure). Such results were mainly due 
to the higher number of off-patent drugs available on the market and not only to 
increased use of generic drugs. In 2004, the percentage of unbranded drugs was 
1.9% and raised until 14.9% in 2013. Despite such growth, Italy was in 2013 the 
third European country (behind Greece and Ireland) for expenditure on branded 
drugs, with a very low uptake vs Germany, France, Spain and UK showing an inci-
dence of generic territorial drug expenditure between 30 and 40%. ConClusions: 
Consumption and expenditure on off-patent drugs has increased in the last 10 years 
in Italy, however the unbranded drugs uptake is still very low when compared with 
other European countries.
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objeCtives: To examine how hospitals’ pharmaceutical cost changes when clinical 
workload indicators are incorporated in the measurement and provide corrective 
estimates to the comparative performance assessment of the MoH for Greek NHS 
hospitals, for 2013. Methods: The study includes annual detailed financial and 
operational data, as recorded by the MoH’s BI system, ESY.net, and analytical data 
on the type of incidents (based on GR-DRGs) recorded, for 129 Greek NHS hospitals. 
